Company intelligence / Profile preview

Longboardism

La Jolla, California, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Bexicaserin (LP352), the lead candidate, is in global Phase III trials for seizures associated with developmental and epileptic encephalopathies. It has shown encouraging anti-seizure activity in preclinical and clinical studies. The program has received Breakthrough Therapy designation, reflecting its potential to address significant unmet needs in rare epilepsy syndromes[4][6].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Beacon Biosignals – strategic partnership for neurophysiological biomarker development using at-home EEG technology focused on rare epilepsies[5]

Beyond the preview

Go deeper on Longboardism.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longboardism.

Explore the full profile